Hourglass Capital LLC Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Hourglass Capital LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 0.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 15,620 shares of the company’s stock after acquiring an additional 140 shares during the quarter. Hourglass Capital LLC’s holdings in Novo Nordisk A/S were worth $1,860,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of NVO. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $26,000. Gilliland Jeter Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Finally, Halpern Financial Inc. lifted its holdings in shares of Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent research reports. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $106.93 on Thursday. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business has a fifty day moving average of $120.23 and a two-hundred day moving average of $130.08. The company has a market cap of $479.83 billion, a P/E ratio of 34.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.42.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.